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| INTRODUC TI ON
With over 400 million cases worldwide, diabetes accounts for 5%-20% of total health expenditures for most countries. 1 In the United States alone, there are 29 million patients living with diabetes and 90%-95% of these are cases of Type 2 Diabetes Mellitus (T2DM). 2 T2DM is defined by elevated blood glucose levels driven by insulin resistance (IR), followed by β-cell dysfunction. Onset of T2DM is usually preceded by a prediabetic phase, classified as impaired fasting glucose (IFG), where blood glucose levels are elevated but below the indicative level for T2DM, impaired glucose tolerance (IGT), or elevated HbA1c. Currently, there are 84 million people in the US who are prediabetic, and it is estimated that up to 70% of these individuals will eventually progress to T2DM. [3] [4] [5] There are currently several approaches that have been employed to halt or reverse the progression toward T2DM in prediabetic individuals, including reducing sugar intake, exercise and weight loss, and the use of glucose lowering drugs like Metformin. [6] [7] [8] While glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels are widely used by clinicians to assess the progression and development of diabetes, they cannot be used to determine the risk of developing T2DM for a prediabetic individual.
Recently, circulating extracellular RNAs, especially microRNAs (miRNAs), present in various body fluids have emerged as potential biomarkers for various diseases and health conditions, including metabolic diseases such as diabetes and obesity. 9 While many miRNAs show promise as biomarkers to distinguish patients with T2DM from healthy individuals, meta-analysis examining specific miRNA concentration differences in plasma between T2DM and healthy individuals show inconsistencies among studies. 10 Many of these discrepancies can be attributed to sample preparation differences and technical issues inherent to various miRNA measurement methods. These factors make the development of circulating miRNA-based biomarkers for T2DM challenging. While qRT-PCR is very well suited for measuring and validating the concentration changes of specific miRNAs especially in clinical setting, small-RNA sequencing (sRNAseq) provides higher dynamic range than qRT-PCR and offers better discrimination between closely related family members, making it a better method for discovery-based miRNA studies. There are several commercial sRNAseq library construction kits available; however, they are prone to introducing significant bias, most likely occurring during adapter-RNA ligation steps. 11, 12 Such biases result in an inaccurate miRNA profile and can cause difficulties when validating the findings.
Additionally, aligning and mapping miRNA can be a challenge due to their small size, and requires a specialized data analysis pipeline
To address issues associated with sRNAseq, we adapted a modified small RNA sequencing library construction method that incorporates four degenerate bases at the appropriate ends of adapters to facilitate the RNA-adapter ligations. This reduces ligation associated bias and provides results that correlate better with qRT-PCR. [13] [14] [15] We have also developed a data analysis pipeline, sRNAnalyzer, 16 which allows for more accurate mapping of small RNA sequencing results. Using these improved methods, we analyzed the spectrum of small RNA from plasma obtained from prediabetic individuals who participated in the METSIM (METabolic Syndrome In Men) study. 17 From the baseline samples analyzed, half of the individuals progressed to T2DM, and the other half remained prediabetic, determined at 5-year follow-up. We identified several circulating extracellular miRNAs that are prognostic at baseline for the transition from prediabetes to T2DM. Some of these miRNAs were also affected by body mass index (BMI), with obese progressors showing greater concentration changes than progressors with a normal BMI. This is the first reported study of this type to look at predictive biomarkers of T2DM years before onset. Table S1 ) between progressors and non-progressors.
| MATERIAL S AND ME THODS

| Sample and study collection
The plasma samples were processed as follows: Blood was collected into EDTA-treated tubes, and spun at 1000 g at 4°C for 10 minutes to remove blood cells, and then 2000 g at 4°C for 15 minutes to remove platelets. Before RNA isolation, the plasma samples were spun at 10 000 g at 4°C for 10 minutes to remove any remaining cellular debris and platelets.
| miRNA isolation and library construction
Circulating RNA was isolated from 75 µL of frozen plasma using the miRNeasy kit (QAIGEN, Germantown, MD) according to the manufacturer's instructions. The RNA was eluted in nuclease-free H 2 0, and the quantity and quality were assessed using a Bioanalyzer and then run on a NextSeq500 sequencer (Illumina, San Diego, CA).
| Data analysis
Sequence files were processed with an in-house small RNA analysis pipeline-sRNAnalyzer. 16 Briefly, the adapters were trimmed from the sequence reads, and low complexity (homo-polymer and simple repeat sequences), low quality and short reads (less than 15 nucleotides) were removed from the file. 
| Novel miRNA analysis
After mapping against the miRNA database, the remaining unmapped reads from samples were combined and run through mirdeep2 18 to identify putative miRNAs. A novel miRNA database was then built and integrated into sRNanalyzer. Unmapped reads from individual samples were then run against the novel miRNA database to determine the number of miRNA candidates in each sample. 
| qRT-PCR
| Identification of predictive miRNA panel
To examine the discrimination power of miRNAs, a classification score was calculated for each sample based on selected miRNAs.
The geometric means of expression levels of the selected miRNAs were used as the classification score. The miRNA sets with the highest discrimination power were identified using greedy search algorithm. 20 In brief, the approach started with the miRNA with the most significant discrimination ability, and then the remaining miRNAs were added one at a time to compute the classification score. Using the score, we calculated the area under the curve (AUC) value from a receiver operating characteristic (ROC) curve. The set of miRNAs showing the highest value of AUC were chosen as the classification panel. To evaluate the classification/prediction performance, we tested the miRNA panels using either all study participants, obese participants, or participants with normal BMI.
| Statistical analysis
The Wilcoxon rank sum statistical test was used to determine the progressors and non-progressors in both small-RNAseq and qRT-PCR. For multiple hypothesis correction, Benjamini-Hochberg was used to identify FDR-corrected P < 0.05, Multivariate analysis of covariance (MANCOVA) was used to identify miRNAs affected by significant differences in FPG between progressors and non-progressors.
| RE SULTS
| Sequencing results
From the 290 prediabetic individuals (Supplemental Table S1 ) that were selected from the METSIM study, 145 of them progressed to T2DM after five years (termed "progressors") and 145 remained at the prediabetic stage (termed "non-progressors"). The samples were matched with respect to BMI and age, but there was a significant difference in the fasting plasma glucose level between the two groups (Table 1) (Table 1) . About 700 different miRNAs were observed (with at least one mapped read) in each sample, among them about 500 miRNAs had 10 or more mapped reads (Table 1) .
| miRNAs associated with disease progression
The Wilcoxon rank sum statistical test was used to identify circulating miRNAs that showed statistically significant concentration differences between progressors and non-progressors. Using >1.5 fold concentration change and P < 0.05 as cut-off, we identified 8 dysregulated miRNAs (miR-122-5p, miR-210-3p, miR-3200-3p, miR-376b-3p, miR378a-3p, miR-4532-5p, miR-483-5p and miR-660-3p) all showing increased concentration in plasma samples from progressors compared to non-progressors ( Figure 1A : Red circles, Table 2 ). Some of the well-known T2DM-associated miRNAs such as miR-375, miR-192-5p, and miR-127-5p showed statistically significant concentration differences between the groups but did not show >1.5 fold concentration changes. We therefore used P < 0.05 as cut-off and fold change >1.2, and identified a total of 57 affected miRNAs ( Figure 1A : Black circles, Table 2 ). To determine if the slight (though significant) difference in FPG between progressors and non-progressors impacted any of these miRNAs, we performed MANCOVA analysis and identified nine of these 57 miRNAs that were affected by FPG (Supplemental Table S2 ), we excluded them for further analysis. From the 48 miRNAs associated with T2DM progression, we selected several (miR-122-5p, miR-127-5p, miR-192-5p, miR-210-3p, miR-29a-5p, miR-3200-3p, miR-375-3p, miR-376b-3p, miR-378a-3p, miR-4532-5p, miR-483-5p, and miR-660-3p, miR-7641-3p, and miR-99a-5p) for qRT-PCR verification on all 290 samples. These were chosen based on an observed fold change of 1.5 or higher (miR-122-5p, miR-210-3p, miR-3200-3p, and miR-376b-3p, miR-378a-3p, miR-4532-5p, and miR-483-5p, miR-660-3p), or a reported association with T2DM but with fold changes between 1.2 and 
| Impact of BMI on disease progression associated circulating miRNA
We also looked at the impact of BMI on the profile of circulating miRNA between progressors and non-progressors, as obesity is a well-known risk factor for developing T2DM. Based on BMI, we grouped the indi- Table 2 ). In contrast, in the progressor groups (PO vs PN), we identified 23 miRNAs, all except three (miR-143-3p, miR-214-3p and miR-1296-5p) of which were elevated in the obese (PO) group compared to normal (PN) ( Figure 2B , Table 2 ). When comparing progressors and non-progressors with normal BMI (PN vs NPN), we observed 10 differentially expressed miRNAs ( Figure 2C , Table 2 ), whereas 17 miRNAs ( Figure 2D , Table 2 ) showed concentration changes in obese individuals (PO vs NPO), of which 14 also showed significant changes between progressors and non-progressors as a whole (Table 2) . Of the 8 miRNAs we originally identified with significant concentration differences between progressors and non-progres- the obese progressor and obese non-progressor groups ( Figure 2E ).
| Novel miRNA and other types of extracellular RNA in circulation
In addition to the known miRNAs, we identified 13 novel miRNA candidates that showed significant concentration changes between progressors and non-progressors (P < 0.05), of which 3 also had a fold change >1.5 ( Figure 3A : Red circles, Supplementary Table S3) and 10 had a fold change <1.5, but>1.2 ( Figure 3A : Black circles, Supplementary Table S3 ). We also looked at the potential impact of BMI on the novel miRNA candidates and found that 9 were significantly elevated in the obese progressors vs obese non-progressors comparison (PO vs NPO) (Supplementary Table S3 ). Of the 3 novel miRNAs we originally identified that showed significant fold changes >1.5 between progressors and non-progressors, 2 were elevated in the PO vs NPO comparison ( Figure 3B , Supplementary Table S3.) Besides miRNAs, our mapping pipeline also provides reads mapped to other types of RNA (Table 1) . We identified a snoRNA, U14A, that was elevated in progressors compared to non-progressors (log2 fold change = 0.61, P = 0.001493); and a piRNA, piRNA-426, that is elevated in PO compared to PN (log2 fold change = 1.08, P = 6.94088E-06) ( Figure 3C,D) .
| Panels of circulating miRNAs to predict the progression of prediabetes to T2DM
We identified a five-miRNA panel (miR-660-3p, miR-3200-3p, miR-4532-5p, miR-122-5p, and miR-378a-3p) that was able to discriminate progressors from non-progressors using receiver operating characteristic (ROC) analysis (AUC = 0.66) ( Figure 4A Figure S3) . We did qRT-PCR validation of the miRNAs in these panels and found that they agreed well with the sRNAseq results ( Figure 4C, D) . 
| Downstream pathways and biological processes associated with dysregulated miRNAs
Using validated miRNA targets, we explored the possible biological processes/pathways that might be affected by the dysregulated miRNAs ( Figure 5 ). A number of signal transduction related processes including the insulin signaling pathway, mTOR signaling pathway, TGF-β signaling pathway, and VEGF signaling pathway, were enriched in this analysis ( Figure 5A ). In addition, there was enrichment for other processes including cell cycle, cell death, metabolism, Table 3 ).
| D ISCUSS I ON
Currently there is no tool that can accurately predict the development of T2DM from prediabetes. By comparing the plasma circulating RNA profiles between two prediabetic groups-one that 
progresses to T2DM after 5 years and the other group remaining at the prediabetic stage-we identified 57 miRNAs showing significant concentration differences between the two groups at baseline (prediabetic stage). When limiting the comparison to obese progressors vs obese non-progressors most of these miRNAs showed even greater concentration differences. We validated some of those miRNAs by qRT-PCR, suggesting that the improvements in library construction and data analysis translate to better cross-platform data consistency, as we have demonstrated previously. 14, 15 Our sequence analysis pipeline also provides novel miRNA candi- and T2DM have used miRNAs for diagnostic purpose and primarily done comparisons among NGT, prediabetes, and T2DM patient cohorts but not on the difference between progressors and non-progressors of prediabetic patients at baseline. [21] [22] [23] Of the 57 miRNAs showing concentration differences between the progressor and non-progressor groups, 26 of them (miR-10b-5p, miR-144-3p, miR-451a-5p, miR-192-5p, miR-125b-5p, miR-101-5p, miR-122-5p, miR-150-5p, miR-17-3p, miR-193a-5p, miR-193b-3p, miR-29c-5p, miR-320a-3p, miR-320b-3p, miR-550a-3p, miR-100-5p, miR-10a-5p, miR-181a-3p, miR-190a-5p, miR-136-5p, miR-375-3p, miR-487b-3p, miR-7-5p, miR-210-3p, miR-378a-3p, and miR-99a-5p) have been previously described as being associated with T2DM based on our recent meta-analysis of the field. 10 We selected 14 miRNAs for qRT-PCR validation and were able to confirm the concentration changes for 10 of these miRNAs (miR-122-5p, miR-127-5p, miR-192-5p, miR-210-3p, miR-3200-3p, miR-375-3p, miR-376b-3p, miR-4532-5p, and miR-660-3p, and miR-7641-3p). Some miRNAs could not be verified with qRT-PCR, probably due to the specific qPCR platform used and high-false negative rate associated with qRT-PCR as previously reported. [24] [25] [26] We investigated the impact of obesity on circulating miRNA and found a notable effect among progressors (Table 2) . Conversely, in the non-progressors the impact of obesity was minimal (only one affected miRNA observed). As expected, obesity also affects miRNAs liver-enriched miRNA that acts in response to insulin to control lipid metabolism. 27, 28 Elevated miR-122-5p levels in serum or plasma have been previously reported to be associated with metabolic syndrome, T2DM, insulin resistance, and obesity. [29] [30] [31] MiR-192 is a liver and pancreatic-enriched miRNA that has been shown to be associated with insulin resistance and is elevated in the plasma of prediabetic individuals, suggesting that elevated levels of miR-192-5p in circulation may signal progression towards T2DM. 31, 32 MiR-210-3p has been previously shown to be involved in adipogenesis, is differentially expressed in visceral adipose tissues in obese T2DM individuals, and is associated with gestational diabetes in obese women. [33] [34] [35] [36] Using validated miRNA targets, we explored the possible biological processes/pathways that might be affected by the dysregulated miRNAs. A number of signal transduction related processes that play important roles in T2DM pathophysiology, including the insulin signaling pathway, mTOR signaling pathway, TGF-β signaling pathway, and VEGF signaling pathway [37] [38] [39] [40] were enriched in this analysis. In addition, these dysregulated miRNAs showed enrichment for other processes including cell cycle, cell death, metabolism, and focal adhesion, which are also involved in T2DM disease progression [41] [42] [43] . Interestingly, many of these pathways and processes showed stronger enrichment in the obese progressors vs non-progressors, compared to progressors vs non-progressors as a whole ( Figure 5A ).
Furthermore, the direct gene targets represent a diverse set of family members associated with these pathways and processes (see Figure 5B , Table 3 ). For example in the cell cycle, miRNAs we find to GALNT7, GALNT10). Interestingly, some of these genes, such as ALDOA and PTPN1, have been to link obesity to T2DM. [44] [45] [46] [47] We also identified two miRNA panels that showed moderate discriminatory ability to distinguish progressors from non-progressors.
As expected, these panels performed better when tested among obese individuals, rather than all individuals, or patients with a normal BMI, which performed the poorest. Interestingly, the best performance (AUC = 0.81) was achieved with the eight miRNA panel testing obese patients, which are at higher risk for developing T2DM. This is probably due to the panel contains several miRNAs (miR-136-5p, miR-490-3p, miR-483-5p) that show concentration differences between obese patients, but not when comparing all patients or patients with normal BMI. The results from qRT-PCR of these miRNAs in obese and normal BMI patients as well as all patients agree with the findings ( Figure 3B ). We propose that the eight-miRNA panel will have better clinical utility when testing obese prediabetic patients. The value of using a "discovery-based" approach over a conventional candidate-based approach is that F I G U R E 5 Biological pathways and processes that might be affected by the dysregulated miRNAs. A, Enrichment of different biological processes and pathways regulated by miRNAs associated with T2DM progression in all patients (white bars) and obese patients (black bars). The miRTar database (mirtarbase.mbc.nctu.edu.tw/) was used to identify validated miRNA targets for gene enrichment (validated by at least two different techniques) and gene enrichment analysis was performed with DAVID (Database for Annotation, Visualization and Integrated Discovery, https://david.ncifcrf.gov/). B, Details of the gene targets (mRNAs) of some of the pathways and processes associated with T2DM progression. MiRNAs (diamonds) associated with T2DM progression are at the top. Different target mRNAs associated with different pathways and processes are shown (Pink-Insulin/PI3K, Purple-TGF-β, blue-cell death/apoptosis, green-cell cycle, red-metabolic process, orange-focal adhesion) with black lines depicting miRNA-mRNA interactions, and light grey lines depicting protein-protein interactions between pathway components as determined by STRING database (https://string-db.org/)
TA B L E 3 Selected miRNAs targets from biological processes and pathways associated with T2DM progression new miRNAs not previously reported to be associated with a given disease or health condition may be identified. While many of the miRNAs we observed have been seen in other T2DM studies, the majority have no known association with T2DM or T2DM progression. We have also identified novel miRNAs not previously characterized, that are associated with T2DM progression and affected by obesity. With further validation, these miRNAs could be considered as promising predictive biomarkers for identifying prediabetic individuals that will progress to T2DM.
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